◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocksAZN › Free Cash Flow

AstraZeneca PLC (AZN) Free Cash Flow 2006–TTM

DATA UPDATED 2026-07-19

AstraZeneca PLC annual free cash flow for fiscal TTM was $8.1 billion, a decrease of 6.9% from $8.7 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

AZN Annual Free Cash Flow

Free Cash Flow (annual)TTM → 2026-03-312025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-31
Free Cash Flow (FCF)$8.1B$8.7B$7.3B$6.6B$7.2B$3.8B$2.2B$509M$1.2B$2.0B$1.8B$536M$4.3B$5.3B$2.3B$6.5B$8.3B$8.8B$4.7B$5.8B$6.4B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AZN Quarterly Free Cash Flow

Free Cash Flow (quarterly)2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Free Cash Flow (FCF)$1.8B$1.4B$3.4B$1.5B$2.7B$2.0B$2.0B$2.4B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

More AZN metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Shares Outstanding

All AZN financial statements → Interactive AZN charts →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.